Efficacy and Safety of SEROQUEL Extended Release (XR) in Acute Schizophrenia

A 3 Weeks Open Label Study to Evaluate the Efficacy in Agitation and Safety of Quetiapine Fumarate XR in Treatment of Patients With Acute Schizophrenia

The purpose of the study is to determine whether treatment with quetiapine XR (Seroquel XR) tablets for 3 weeks will improve their agitation when they have acute psychosis.

Inclusion Criteria:

• Requirement for treatment of acute episode of schizophrenia (according to DSM-IV diagnostic criteria)
• PANSS total score of ³ 75
• CGI > 4

Exclusion Criteria:

• Any DSM-IV (Diagnostic and Statistical Manual of Mental Disorders 4th Edition) Axis I disorder not defined in the inclusion criteria
• Patients who, in the opinion of the investigator, pose an imminent risk of suicide or a danger to self or others
• Substance or alcohol dependence at enrollment